Visit optimas.org.uk for the up-to-date website.
5 April 2018
Chief Investigator: Professor David Werring (UCL)
OPTIMAS is a multicentre randomised controlled trial of early vs standard, guideline-based timing of anticoagulation with a DOAC in patients with atrial fibrillation and acute ischaemic stroke.
Eligibility: Adult patients with nvAF and clinical diagnosis of acute ischaemic stroke, eligible for DOAC treatment.
Intervention: Anticoagulation with any DOAC within 4 days of acute ischaemic stroke
Control: Anticoagulation with any DOAC at 7—14 days of acute ischaemic stroke
Key Outcomes: combined incidence of symptomatic ICH, ischaemic stroke and systemic embolism at 90 days; intracranial and major extracranial bleeding
Imaging: encouraged but no specific requirements for study entry
First recruit: July 2019
Recruitment to date: 897 (17 May 2021)
Target sites: >100 in UK (115 EoI to date)
Sites activated to date: 78 (17 May 2021)
- Jonathan G Best, Liz Arram, Norin Ahmed, Maryam Balogun, Kate Bennett, Ekaterina Bordea, Marta G Campos, Emilia Caverly, Marisa Chau, Hannah Cohen, Hakim-Moulay Dehbi, Caroline J Doré, Stefan T Engelter, Robert Fenner, Nick Freemantle, Rachael Hunter, Martin James, Gregory YH Lip, Macey L Murray, Bo Norrving, Nikola Sprigg, Roland Veltkamp, Iwona Zaczyk, David J Werring, the OPTIMAS investigators | Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial | doi.org/10.1177/17474930211057722